QPPV.COM KNOWLEDGE ASSESSMENT

Dostarlimab: Classification, History, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Dostarlimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which approach is most appropriate for signal detection involving Dostarlimab?

Stratify or otherwise examine relevant populations and align case definitions, laboratory evidence, exposure denominators and severity before concluding Count every related preferred term together without medical review to maximise sensitivity Use only spontaneous report counts because background disease rates are not relevant Interpret a cluster as confirmed causality as soon as it exceeds a numerical threshold

Question 2 of 10 A case describes pneumonitis shortly after Dostarlimab exposure. Which information would most directly improve assessment of competing causes?

Serial respiratory findings and imaging together with infection evaluation, disease status and relevant prior or concomitant therapies The patient’s preferred method of receiving appointment reminders The colour and size of the outer carton only The date on which the report was entered into the safety database

Question 3 of 10 Which finding would most strengthen a hypothesis of a Dostarlimab-associated organ-specific immune-mediated injury?

A compatible phenotype with objective serial abnormalities, a plausible chronology and no stronger competing explanation A symptom recorded without examination, testing or timing information A pre-existing identical abnormality that clearly preceded treatment and remained unchanged A report containing only the patient’s tumour stage and no information about the event

Question 4 of 10 A reviewer receives a report of fever during Dostarlimab treatment. What is the most appropriate initial interpretation?

Fever requires differential assessment because infection, inflammation, administration reaction and disease-related causes may overlap Fever should automatically be classified as an immune-mediated adverse reaction Fever can be disregarded unless it occurs after the final treatment cycle Fever establishes treatment failure because it indicates worsening cancer

Question 5 of 10 Which statement best reflects the role of absence of reports in periodic benefit-risk evaluation?

A lack of reports does not prove absence of risk, particularly when an event is difficult to recognise or the population is specialised A lack of reports proves that the event cannot occur with Dostarlimab A lack of reports removes the need for targeted follow-up and active monitoring A lack of reports establishes that the treatment benefit outweighs all possible risks

Question 6 of 10 Which set of factors best reflects the three-layer safety architecture described for Dostarlimab?

PD-1 pathway effects, patient susceptibility, and disease or treatment environment Batch number, marketing authorisation holder, and reporting country only Tumour histology, patient preference, and pharmacy dispensing frequency only Dose strength, packaging colour, and administration-room location only

Question 7 of 10 Which operational control would best help identify delayed or recurrent Dostarlimab-related events?

Follow-up that continues beyond the next scheduled dose when clinically relevant and records persistence, recurrence and interruption status Closing every case at the next scheduled administration regardless of clinical course Recording only the initial symptom and omitting subsequent outcomes Restricting follow-up to product batch information

Question 8 of 10 A report labels an event as “immune-mediated hepatitis” but contains no laboratory results, imaging, treatment details or alternative-cause assessment. What is the main pharmacovigilance concern?

The label is unsupported by the available evidence and may obscure the distinction between treatment effect, disease and other causes The label is sufficient because mechanistic terminology does not require clinical support The case should be closed because immune-mediated events cannot be assessed retrospectively The event should be coded only as a product-quality complaint

Question 9 of 10 Which follow-up request is most appropriate for a suspected serious infection in a Dostarlimab case?

Site of infection, organism and cultures, imaging, antimicrobial treatment, immune status and outcome Only the patient’s prior tumour response, without infection-specific information Only the product batch, without clinical findings or treatment details A request asking whether the reporter believes the event is related, without supporting evidence

Question 10 of 10 Which factor should be considered when evaluating whether an apparent Dostarlimab signal reflects an increase in reporting rather than an increase in event occurrence?

Reporting stimulation, changes in clinical practice, indication mix and background disease rates Only the number of available carton designs The existence of a product label, without any review of case characteristics Whether the event term appears alphabetically early in the database

QPPV.com

Dostarlimab: Classification, History, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings